北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Recipient expression of ligands for donor inhibitory KIRs enhances NK-cell function to control leukemic relapse after haploidentical transplantation
作者: Zhao, Xiang-Yu1; Chang, Ying-Jun1; Zhao, Xiao-Su1; Xu, Lan-Ping1; Zhang, Xiao-Hui1; Liu, Kai-Yan1; Li, Dan1; Huang, Xiao-Jun1,2
关键词: KIR ; Haploidentica ; HSCT ; NK cells ; T-cell replete ; Leukemia
刊名: EUROPEAN JOURNAL OF IMMUNOLOGY
发表日期: 2015-08-01
DOI: 10.1002/eji.201445057
卷: 45, 期:8, 页:2396-2408
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Immunology
研究领域[WOS]: Immunology
关键词[WOS]: NATURAL-KILLER-CELLS ; HLA-MISMATCHED/HAPLOIDENTICAL BLOOD ; ACUTE MYELOID-LEUKEMIA ; CLASS-I MOLECULES ; CYTOMEGALOVIRUS-INFECTION ; MARROW TRANSPLANTATION ; HEMATOPOIETIC TRANSPLANTS ; RECEPTOR EXPRESSION ; CLINICAL-OUTCOMES ; EFFECTOR FUNCTION
英文摘要:

Natural killer (NK) cells that express self-HLA-specific receptors (where HLA is human leukocyte antigen) are "licensed" and more readily activated than unlicensed cells; therefore, NK-cell licensing could influence the antileukemia effects of NK cells following haploidentical stem cell transplantation (haplo-SCT). In this study, we compared the functionality of reconstituting NK cells, based on CD107 alpha expression and interferon-ysecretion, in a cohort of 29 patients that expressed (n = 8) or lacked (n = 21) class I human leukocyte antigens for donor inhibitory killer cell immunoglobulin-like receptors (KIRs) following T-cell-replete haplo-SCT. We also addressed whether recipient expression of class I ligands for donor inhibitory KIRs could predict relapse occurrence in another cohort of 188 patients. A longitudinal analysis indicated that patients presenting class I for all donor inhibitory KIRs showed more capable functional NK effector cells when tested against class I negative K562 cells and primary leukemic cells within 3 months of transplantation. The lowest 7-year relapse incidence was observed when donor KIRs were ligated by recipient class I (n = 60) compared with donor host partnerships where donor KIR+ cells were ligated by donor, but not recipient class I (n = 86, p = 0.026) or KIRs that were ligated by neither donor nor recipient class I (n = 42, p = 0.043). This study suggests that haplo-SCT recipients presenting class I for donor inhibitory KIRs promote NK-cell licensing, leading to decreased relapse rates.

语种: 英语
所属项目编号: 81270644 ; 81230013 ; 2013CB733700 ; 20110001110039
项目资助者: National Natural Science Foundation of China ; Major State Basic Research Development Program of China (973 Program) ; Collaborative Innovation Center of Hematology, Peking University, China ; Ministry of Education of China ; Milstein Medical Asian American Partnership (MMAAP) Foundation Research Project Award in Hematology
WOS记录号: WOS:000359674200024
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/56301
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
2.Peking Univ, Inst Hematol, Peoples Hosp, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100871, Peoples R China

Recommended Citation:
Zhao, Xiang-Yu,Chang, Ying-Jun,Zhao, Xiao-Su,et al. Recipient expression of ligands for donor inhibitory KIRs enhances NK-cell function to control leukemic relapse after haploidentical transplantation[J]. EUROPEAN JOURNAL OF IMMUNOLOGY,2015,45(8):2396-2408.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhao, Xiang-Yu]'s Articles
[Chang, Ying-Jun]'s Articles
[Zhao, Xiao-Su]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhao, Xiang-Yu]‘s Articles
[Chang, Ying-Jun]‘s Articles
[Zhao, Xiao-Su]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2018  北京大学医学部 - Feedback
Powered by CSpace